Shortage pharmaceuticals blood products such as: carimune; oncological pharmaceuticals such as: vinblastine, novoseven and other relevant pharmaceuticals products including injectables, orals and…
Ended Awarded Last action
- Contract number
- HT001417F0230
- Awardee
-
Broughton Pharmaceuticals, LLC UEI J949HUF889Y1
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $299,473
Award facts
- Contract value 100% obligated
- $299,472.93 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 3 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20889, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$527 | |
| Original award | $300,000 |
About this award
This federal contract award is to Broughton Pharmaceuticals, LLC, a for-profit limited liability company based in Savannah, Georgia. The contract, awarded by the Defense Health Agency (DHA), is a Blanket Purchase Agreement (BPA) with a ceiling value of $2,000,000 that extends through September 24, 2024.
Under this BPA, Broughton Pharmaceuticals provides a variety of pharmaceutical products to support the DHA's operations, particularly for the Walter Reed National Military Medical Center in Bethesda, Maryland. The contract covers a range of medications, including shortage pharmaceuticals, oncological drugs, and specialized products such as Tice BCG vaccine, sodium bicarbonate, and epinephrine. This contract was awarded without a set-aside designation.
Description
Shortage pharmaceuticals blood products such as: carimune; oncological pharmaceuticals such as: vinblastine, novoseven and other relevant pharmaceuticals products including injectables, orals and medicinal inhalations.
Quick answers
Who was awarded contract HT001417F0230?
HT001417F0230 was awarded to Broughton Pharmaceuticals, LLC by Defense Health Agency (Department of Defense) on August 14, 2017.
How much is contract HT001417F0230 worth?
The government has obligated $299,473 on HT001417F0230.
Is contract HT001417F0230 an order under another contract?
Yes. HT001417F0230 is a BPA call under HT001414A0014, a blanket purchase agreement.
Was contract HT001417F0230 competed?
The extent of competition for HT001417F0230 was competed under sap. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award